Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

NCT05509595 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Fibrous Dysplasia Of Bone

Interventions

DRUG: Burosumab

Sponsor

National Institute of Dental and Craniofacial Research (NIDCR)